SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1131From Morningstar: Amgen's AMGN second-quarter earnings released Thursday afmopgcw-7/25/2004
1130ml report: Message 20338457mopgcw-7/24/2004
1129AMGEN beats by 3 cents or so, a solid quarter. Those of us who thought AMGN paituck-7/22/2004
1128SSB: For Amgen (AMGN), we expect solid product sales. Based on our analysis omopgcw-7/9/2004
1127Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to mopgcw-6/28/2004
1126GS: AMGN(OP/N): Neulasta market may expand with new data 52-Week Range US$72-53mopgcw-6/27/2004
1125Amgen Submits Biologics License Application for FDA Approval of Palifermin Thursmopgcw-6/24/2004
1124GS: AMGN(OP/N): Positive update highlights growth 52-Week Range US$72-54 YTD Pmopgcw-6/14/2004
1123Thanks for the updates. AMGN price and valuation look attractive to me comparedPaul Senior-6/7/2004
1122GS: AMGN/DNA/GILD: Differential impact of ESO expensing on biotech. CC Today @10mopgcw-6/2/2004
1121GS: AMGN(OP/N): Meetings with CEO confirmed long-term positive view 52-Week Ranmopgcw-6/2/2004
1120this is a teststeve from ihub-5/28/2004
1119The latest from SSB.... United S ta tes May 20, 2004 BIOTECHNOLOGY Elise Wang SSirWalterRalegh-5/21/2004
1118HERRINGER FRANK C,Director,BUYS 5,000 ON 5/14/04 OF AMGN 2004-05-17 21:32 (New Ymopgcw-5/18/2004
1117Thanks for this, and others. Maykin Ho seems to be making hay (ie pretty darn bFiloF-5/5/2004
1116GS: AMGN (OP/N): Limited impact from FDA review of Aranesp. Maintain estimates mopgcw-5/5/2004
1115GS: AMGN/DNA(OP/N): First take: Updates on Roche R&D Day within expectation mopgcw-5/5/2004
1114>>GAITHERSBURG, Md., May 4 (Reuters) - A U.S. advisory panel voiced supportuck-5/4/2004
1113GS: Analyst Comment Stock rating: Outperform Coverage view: Neutral Large-Cap Gmopgcw-4/21/2004
1112From Barron's : By BILL ALPERT Inside Amgen's Laboratory AMGEN ASKEDmopgcw-3/31/2004
1111GS: AMGN(OP/N): Unwarranted weakness after R&D Day. Maintain Outperform &mopgcw-3/30/2004
1110>>BusinessWeek Online Amgen Opens The Secret Curtain Friday March 12, 3:5tuck-3/12/2004
1109AMGN and other select biotech stocks gained over 4% for the week. Biotechnology blackmerlin-12/20/2003
1108AMGN off of a high round 70...down to 62. Anybody got a feeling as to why the suOrcastraiter-10/21/2003
1107Zacks Issues Buy Recommendations on the Following 4 Stocks: Amgen, Coventry HealREH-6/12/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News